IndiaRF to acquire Ind-Swift Labs API, CRAMS business for Rs 1650 crores

Mumbai: The Board of Directors of Ind-Swift Laboratories Limited (“IndSwift”) have approved a business transfer of its active pharmaceutical ingredients (“API”) and contract research and manufacturing services (“CRAMS”) business to Synthimed Labs Private Limited, a portfolio company of India Resurgence Fund (“IndiaRF”).

IndiaRF, a Indiafocused investment platform promoted by Piramal Enterprises Limited and Bain Capital, will acquire the business for a consideration of INR 1,650 crores.

Ind-Swift is amongst the top ten independent merchant API businesses in India in size, with two manufacturing sites in Punjab and Jammu, and a combined reactor capacity of ~700 KL catering to both regulated and unregulated markets. The API business has diverse therapeutic presence across the US, Japan, Korea, EU, Brazil and India. Ind-Swift reported a consolidated revenue of INR 1,207 Cr and consolidated EBITDA of INR 256 Cr in FY23. Shareholder and regulatory approvals are required for the completion of the transaction. Synthimed will also acquire an intermediate manufacturing facility from the promoter group.

Commenting on the transaction, Shantanu Nalavadi, Managing Director of IndiaRF, said, “IndiaRF is excited about the transformation potential of Ind-Swift. Ind-Swift has a strong market presence and competitive cost position. We believe the business needs the necessary capital infusion for it to acquire scale and move upwards in the growth trajectory. We are committed to invest further primary capital into the businesses to expand capacity on back of growth from newer geographies and investment in new product development across both API and CRAMS, to provide a larger portfolio of products to its customers.”

N R Munjal, Chairman and Managing Director of Ind-Swift on this occasion said “Ind-Swift is amongst the largest independent API players in India and has had the track recording of developing API molecules with customer centric approach and has created high quality facilities. We are delighted that IndiaRF, which has a pedigree and track record in transforming businesses across varied sectors, will support and invest in the growth of the business. We are grateful to our team and wish them the best to scale the business to newer heights under the IndiaRF’s stewardship.”

PwC acted as the exclusive financial advisor to Ind-Swift on this transaction.

Read also: Piramal Pharma gets SEBI go ahead to raise up to Rs 1050 crore through rights issue